| Revision as of 12:53, 29 January 2023 editEntranced98 (talk | contribs)Extended confirmed users, Pending changes reviewers, Rollbackers172,831 edits Importing Wikidata short description: "Chemical compound"Tag: Shortdesc helper← Previous edit | Latest revision as of 09:49, 10 January 2024 edit undoMaxim Masiutin (talk | contribs)Extended confirmed users, IP block exemptions, Pending changes reviewers31,043 edits Added s2cid. Added the cs1 style template to denote Vancouver ("vanc") citation style, because references contain "vauthors" attribute to specify the list of authors. | ||
| Line 1: | Line 1: | ||
| {{Short description|Chemical compound}} | {{Short description|Chemical compound}} | ||
| {{cs1 config|name-list-style=vanc}} | |||
| {{Drugbox | {{Drugbox | ||
| | Watchedfields = changed | | Watchedfields = changed | ||
| Line 52: | Line 53: | ||
| }} | }} | ||
| '''ADX-47273''' is a research pharmaceutical developed by ] which acts as a ] (PAM) selective for the ] subtype ].<ref name="pmid16722652">{{cite journal |vauthors =de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ |title=Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes |journal=Journal of Medicinal Chemistry |volume=49 |issue=11 |pages=3332–44 |date=June 2006 |pmid=16722652 |doi=10.1021/jm051252j }}</ref><ref>{{cite journal|last1=Stauffer|first1=Shaun R.|title=Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu5)|journal=ACS Chemical Neuroscience|date=17 August 2011|volume=2|issue=8|pages=450–470|doi=10.1021/cn2000519|pmc=3369763|pmid=22860171}}</ref> It has ] and ] effects in animal studies,<ref name="pmid18753411">{{cite journal |vauthors =Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL |title=ADX47273 -oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=327 |issue=3 |pages=827–39 |date=December 2008|pmid=18753411 |doi=10.1124/jpet.108.136580 }}</ref> and has been used as a ] to develop improved derivatives.<ref name="pmid19197923">{{cite journal |vauthors =Engers DW, Rodriguez AL, Williams R, Hammond AS, Venable D, Oluwatola O, Sulikowski GA, Conn PJ, Lindsley CW |title=Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273 |journal=ChemMedChem |volume=4 |issue=4 |pages=505–11 |date=April 2009 |pmid=19197923 |doi=10.1002/cmdc.200800357 |pmc=2865690}}</ref> | '''ADX-47273''' is a research pharmaceutical developed by ] which acts as a ] (PAM) selective for the ] subtype ].<ref name="pmid16722652">{{cite journal |vauthors =de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ |title=Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes |journal=Journal of Medicinal Chemistry |volume=49 |issue=11 |pages=3332–44 |date=June 2006 |pmid=16722652 |doi=10.1021/jm051252j }}</ref><ref>{{cite journal|last1=Stauffer|first1=Shaun R.|title=Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu5)|journal=ACS Chemical Neuroscience|date=17 August 2011|volume=2|issue=8|pages=450–470|doi=10.1021/cn2000519|pmc=3369763|pmid=22860171}}</ref> It has ] and ] effects in animal studies,<ref name="pmid18753411">{{cite journal |vauthors =Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL |title=ADX47273 -oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities |journal=The Journal of Pharmacology and Experimental Therapeutics |volume=327 |issue=3 |pages=827–39 |date=December 2008|pmid=18753411 |doi=10.1124/jpet.108.136580 |s2cid=19362501 }}</ref> and has been used as a ] to develop improved derivatives.<ref name="pmid19197923">{{cite journal |vauthors =Engers DW, Rodriguez AL, Williams R, Hammond AS, Venable D, Oluwatola O, Sulikowski GA, Conn PJ, Lindsley CW |title=Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273 |journal=ChemMedChem |volume=4 |issue=4 |pages=505–11 |date=April 2009 |pmid=19197923 |doi=10.1002/cmdc.200800357 |pmc=2865690}}</ref> | ||
| ==See also== | ==See also== | ||
Latest revision as of 09:49, 10 January 2024
Chemical compoundPharmaceutical compound
 | |
| Identifiers | |
|---|---|
IUPAC name
| |
| CAS Number |
|
| PubChem CID | |
| IUPHAR/BPS | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| Chemical and physical data | |
| Formula | C20H17F2N3O2 |
| Molar mass | 369.372 g·mol |
| 3D model (JSmol) | |
SMILES
| |
InChI
| |
| (verify) | |
ADX-47273 is a research pharmaceutical developed by Addex Therapeutics which acts as a positive allosteric modulator (PAM) selective for the metabotropic glutamate receptor subtype mGluR5. It has nootropic and antipsychotic effects in animal studies, and has been used as a lead compound to develop improved derivatives.
See also
References
- de Paulis T, Hemstapat K, Chen Y, Zhang Y, Saleh S, Alagille D, Baldwin RM, Tamagnan GD, Conn PJ (June 2006). "Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes". Journal of Medicinal Chemistry. 49 (11): 3332–44. doi:10.1021/jm051252j. PMID 16722652.
- Stauffer SR (17 August 2011). "Progress toward Positive Allosteric Modulators of the Metabotropic Glutamate Receptor Subtype 5 (mGlu5)". ACS Chemical Neuroscience. 2 (8): 450–470. doi:10.1021/cn2000519. PMC 3369763. PMID 22860171.
- Liu F, Grauer S, Kelley C, Navarra R, Graf R, Zhang G, Atkinson PJ, Popiolek M, Wantuch C, Khawaja X, Smith D, Olsen M, Kouranova E, Lai M, Pruthi F, Pulicicchio C, Day M, Gilbert A, Pausch MH, Brandon NJ, Beyer CE, Comery TA, Logue S, Rosenzweig-Lipson S, Marquis KL (December 2008). "ADX47273 -oxadiazol-5-yl]-piperidin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities". The Journal of Pharmacology and Experimental Therapeutics. 327 (3): 827–39. doi:10.1124/jpet.108.136580. PMID 18753411. S2CID 19362501.
- Engers DW, Rodriguez AL, Williams R, Hammond AS, Venable D, Oluwatola O, Sulikowski GA, Conn PJ, Lindsley CW (April 2009). "Synthesis, SAR and unanticipated pharmacological profiles of analogues of the mGluR5 ago-potentiator ADX-47273". ChemMedChem. 4 (4): 505–11. doi:10.1002/cmdc.200800357. PMC 2865690. PMID 19197923.
 | This drug article relating to the nervous system is a stub. You can help Misplaced Pages by expanding it. |